KDS12025
Based on 1 Customer Validation
KDS12025 is a blood-brain barrier-permeable, orally active H2O2-decomposing peroxidase enhancer. KDS12025 enhances the H2O2-decomposing pseudoperoxidase activity of Hb without altering oxygen transport function, and reduces intracellular H2O2 load. KDS12025 reduces abnormal H2O2 levels and inhibits the production of COL1. KDS12025 restores cerebral blood flow, maintains neuronal excitability, membrane properties, synaptic connections and corticospinal tract fibers, reduces cerebral edema and exerts neuroprotective effects. KDS12025 improves motor function and overall neurological function. KDS12025 can be used in the research of ischemic stroke, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, aging-related neurodegenerative diseases and rheumatoid arthritis.
For research use only. We do not sell to patients.
- Purity : 99.74%
- CAS No.: 2769053-56-5
- Formula: C16H20N2O
- Molecular Weight:256.34
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Description
In Vitro
KDS12025 significantly protects primary cortical neurons against astrocyte-mediated in vitro neurotoxicity induced by H2O2[1].
KDS12025 (1 μM; 30 min) potently enhances the H2O2-decomposing pseudoperoxidase activity of purified hemoglobin, with an EC50 of 0.04 μM, and effectively achieves H2O2 decomposition even at extremely low Hb concentrations[2].
KDS12025 (10 μM; 24 h) effectively reduces H2O2 levels induced by Aβ, putrescine and 6-OHDA (HY-B1081) in primary cultured hippocampal astrocytes, with an EC50 of 0.5 μM, and its antioxidant effect depends on Hbβ in astrocytes[2].
KDS12025 binds strongly to the proximal heme site of the hemoglobin β subunit with a binding energy of −16.5 kcal/mol, thereby enhancing the pseudoperoxidase activity of Hb[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
KDS12025 (1 mg/kg/day; p.o.; ad libitum in drinking water; 4 weeks) fully restores motor function and reverses Parkinson's disease-related pathology in A53T α-synuclein mice, with efficacy dependent on both astrocytic and neuronal Hbβ[2].
KDS12025 (0.1-1 mg/kg/day; p.o.; ad libitum in drinking water; 22 months) increases median survival by ~14%, restores locomotor function, prevents neuronal loss, reverses astrocytic atrophy, and restores astrocytic Hbβ levels in aging C57BL/6J mice[2].
KDS12025 (0.1-10 mg/kg/day; i.p., p.o.; daily, ad libitum in drinking water; 7 days, 2 weeks, 16 days) potently reverses Alzheimer's disease-related memory impairment, neurodegeneration, astrogliosis, oxidative stress, and neuronal dysfunction in APP/PS1 mice, with efficacy dependent on astrocytic Hbβ[2].
KDS12025 (1 mg/kg/day) mitigates rheumatoid arthritis pathology and systemic inflammation in collagen-induced arthritis mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:APP/PS1 mice (10-18 months old, both sexes)[2]
-
Dosage:3 mg/kg/day; 10 mg/kg/day; 0.1 mg/kg/day
-
Administration:i.p.; daily; 16 days, 7 days; p.o.; ad libitum in drinking water; 2 weeks, 16 days
-
Result:Improved memory impairment.
Reduced hippocampal reactive astrocyte (GFAP) and microglia (Iba1) levels.
Reversed astrogliosis.
Normalized aberrant tonic GABA currents.
Restored astrocytic hemoglobin β (Hbβ) levels.
Reduced oxidative stress marker 8-OHdG levels.
Normalized astrocytic GABA levels.
Restored neuronal spike probability.
Abolished all effects following astrocytic Hbβ gene silencing.
-
Animal Model:A53T α-synuclein overexpression mice[2]
-
Dosage:1 mg/kg/day
-
Administration:p.o.; ad libitum in drinking water; 4 weeks
-
Result:Rescued motor impairment.
Reversed tyrosine hydroxylase (TH)-positive dopaminergic neuronal loss.
Reduced astrogliosis.
Normalized abnormally elevated astrocytic GABA levels.
Restored astrocytic and neuronal Hbβ levels.
Partially abolished effects following either astrocytic or neuronal Hbβ gene silencing.
-
Animal Model:C57BL/6J mice (14 months old, female)[2]
-
Dosage:0.1 mg/kg/day; 1 mg/kg/day
-
Administration:p.o.; ad libitum in drinking water; 22 months
-
Result:Increased median survival by ~14% in both dose groups.
Enabled 46.7% of female mice to survive to 31 months when all control mice had died.
Restored locomotor function in 26-month-old mice to levels comparable to 12-month-old mice.
Prevented neuronal loss in the hippocampal CA1 region.
Preserved TH-positive dopaminergic neurons in the substantia nigra pars compacta.
Reversed astrocytic atrophy, restoring astrocytic arborization to 18-month-old control levels.
Restored reduced astrocytic Hbβ levels to exceed those in 18-month-old mice.
Chemical Information
-
CAS No. 2769053-56-5
-
Appearance Oil
-
Molecular Weight 256.34
-
Formula C16H20N2O
-
Color Yellow to brown
-
SMILES
CNC(C=C1)=CC=C1NCCC2=C(C=CC=C2)OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Protocols
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Neuronal voltage-sensitive dye imaging
Neuronal voltage-sensitive dye imaging detects membrane-potential-dependent optical changes from dyes associated with neuronal membranes, enabling optical recording of electrical activity from single neurons, dendrites, axons, spines, or neuronal populations in brain slices and cultured neurons. VSD signals are typically reported as fractional fluorescence or absorbance changes over baseline, such as ΔF/F or ΔI/I, and published protocols use high-speed cameras or photodiode arrays because neuronal voltage signals occur on millisecond time scales. Fast VSD imaging can be applied at two common scales: bulk staining of brain slices to measure circuit-level spatiotemporal activity, and single-cell loading or biolistic delivery to record membrane-potential transients from individual neuronal compartments. Optical signals should be interpreted as membrane-potential-related readouts, and validation by simultaneous electrophysiology or pharmacological controls is recommended when the experimen
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
-
Cell-attached patch-clamp recording
Cell-attached patch-clamp recording measures ionic current through one or more ion channels in a small membrane patch that remains attached to an intact cell; the readout is a time-resolved current trace generated when channels in the sealed patch open and close under controlled pipette voltage or stimulus conditions. Classic applications include single acetylcholine receptor currents in frog skeletal muscle, single sodium-channel currents in cultured rat muscle cells, one-channel NMDA receptor recordings, and mechanically activated PIEZO-channel recordings. The method depends on forming a high-resistance pipette-membrane seal, commonly described as a gigaohm seal, which reduces leak and noise sufficiently to resolve picoampere-scale single-channel currents. In the cell-attached configuration, the patch membrane is not ruptured, so cytosolic composition is not directly dialyzed by the pipette solution.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)